

Please type a plus sign (+) inside this box → Approved for use through 10/31/98. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/719,080
(use as many sheets as necessary)				Filing Date	11-21-2003
				First Named Inventor	GRAUPE
				Group Art Unit	1626
				Examiner Name	Anderson, Rebecca
Sheet	1	of	13	Attorney Docket Number	USAV2001/0082 - US - CNT

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.*	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ³ (if known)			
RA	4,927,809	STUBER, et al.		05-22-1990		
RA	5,424,925	ANDO, et al.		06-13-1995		
RA	5,486,623	ZIMMERMAN, et al.		01-23-1996		
RA	5,498,616	MALLANO, et al.		03-12-1996		
RA	5,847,135	BEMIS, et al.		12-08-1998		
RA	5,852,007	CHATTERJEE, et al.		12-22-1998		
RA	5,874,424	BATCHELOR, et al.		02-23-1999		
RA	6,098,390	RAMAMURTHY, et al.		12-07-1999		
RA	6,004,833	SPRUCE, et al.		12-21-1999		
RA	6,022,861	SCARBOROUGH, et al.		02-08-2000		
RA	6,114,310	CHAMBERLAND, et al.		09-05-2000		
RA	6,124,333	MILLER, et al.		12-26-2000		
RA	6,255,453	GYORKOS		07-03-2001		
RA	6,355,017	ALTMAN, et al.		03-05-2002		
RA	6,455,502	BRYANT, et al.		09-24-2002		
RA	6,476,028	BRYANT, et al.		11-05-2002		
RA	6,482,362	GRAUPE, et al.		12-10-2002		
RA	6,606,733	BUYSSE		01-14-2003		
RA	6,576,630	LINK, et al.		06-10-2003		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.*	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ⁴	Number ⁴	Kind Code ⁵ (if known)			
RA	EP	EP 0272671			KRANTZ, et al.	06-29-1988	
RA	EP	EP 0291234			EDWARDS, et al.	11-17-1998	
RA	EP	EP 0355572			PAQUES, et al.	02-28-1990	
RA	EP	EP 0376012			ALBRIGHT, et al.	07-04-1990	
RA	EP	EP 0418683			HARA, et al.	04-03-1991	
RA	EP	EP 0536399			OKUBO, et al.	04-01-1993	
RA	EP	EP 0652009			DOVEY, et al.	10-05-1995	
RA	EP	EP 0754454			KOBAYASHI, et al.	01-22-1997	
RA	JP	JP 06192199			RYOICHI, et al.	07-12-1994	
RA	JP	JP 42009133			IRIKURA, et al.	05-06-1997	

Examiner Signature	/Rebecca Anderson/	Date Considered	06/13/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (MPEP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office 118 DEPARTMENT OF COMMERCE

<p>Substitute for Form 1448A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>		<p>Complete If Known</p>	
Sheet	2	of	13
		Application Number	10/719,080
		Filing Date	11-21-2003
		First Named Inventor	GRAUPE
		Group Art Unit	1628
		Examiner Name	Anderson, Rebecca
		Attorney Docket Number	USAV2001/0082 - US - CNT

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initiator ¹	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ²	Number ²	Kind Code ² (if known)		
RA	JP	JP 63303888		YOSHIDA, et al.	12-08-1988	
RA	WO	WO 00/48892		TUCKER, et al.	08-24-2000	
RA	WO	WO 00/49007		TUCKER, et al.	08-24-2000	
RA	WO	WO 00/49008		TUCKER, et al.	08-24-2000	
RA	WO	WO 00/51888		CYWIN, et al.	09-08-2000	
RA	WO	WO 00/59861		SINGH, et al.	10-12-2000	
RA	WO	WO 00/69855		QUIBELL, et al.	11-23-2000	
RA	WO	WO 01/09110		BEKKALI, et al.	02-08-2001	
RA	WO	WO 01/19796		GRAUPE, et al.	03-22-2001	
RA	WO	WO 01/18808		GRAUPE	03-22-2001	

Examiner Signature	/Rebecca Anderson/	Date Considered	06/13/2006
-----------------------	--------------------	--------------------	------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.9). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-90)
Approved for use through 10/31/99. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/719,080
		Filing Date	11-21-2003
		First Named Inventor	GRAUPE
		Group Art Unit	1628
		Examiner Name	Anderson, Rebecca
Sheet	3	of	13
		Attorney Docket Number	USAV2001/0082 - US - CNT

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ²	Number ³	Kind Code ² (if known)		
RA	WO	WO 01/19816		EMMANUEL, et al.	03-22-2001	
RA	WO	WO 01/30772		TUCKER, et al.	05-03-2001	
RA	WO	WO 01/55125		BOZSING, et al.	08-02-2001	
RA	WO	WO 01/58886		MISSBACH, M	08-18-2001	
RA	WO	WO 95/13069		MORRIELLO, et al.	05-18-1995	
RA	WO	WO 95/15309		JENKINS, et al.	06-08-1995	
RA	WO	WO 95/24382		HALLINAN, et al.	09-14-1995	
RA	WO	WO 96/21655		PEET, et al.	07-18-1996	
RA	WO	WO 96/30353		PALMER, et al	10-03-1996	
RA	WO	WO 96/40647		ZIMMERMAN, et al.	12-19-1996	

Examiner Signature	/Rebecca Anderson/	Date Considered	06/13/2006
-----------------------	--------------------	--------------------	------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Protection of Information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for Form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				<p>Complete If Known</p> <table border="1"> <tr> <td>Application Number</td> <td>10/719,080</td> </tr> <tr> <td>Filing Date</td> <td>11-21-2003</td> </tr> <tr> <td>First Named Inventor</td> <td>GRAUPE</td> </tr> <tr> <td>Group Art Unit</td> <td>1626</td> </tr> <tr> <td>Examiner Name</td> <td>Anderson, Rebecca</td> </tr> </table>		Application Number	10/719,080	Filing Date	11-21-2003	First Named Inventor	GRAUPE	Group Art Unit	1626	Examiner Name	Anderson, Rebecca
Application Number	10/719,080														
Filing Date	11-21-2003														
First Named Inventor	GRAUPE														
Group Art Unit	1626														
Examiner Name	Anderson, Rebecca														
Sheet	4	of	13	Attorney Docket Number											
USAV2001/0082 - US - CNT															

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office ³	Number ⁴	Kind Code ⁵ (if known)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
RA	WO	WO 96/40744		MARLOWE, et al.	12-19-1996
RA	WO	WO 96/41638		DOLLE, et al.	12-27-1996
RA	WO	WO 97/03679		MALLANO, et al.	02-08-1997
RA	WO	WO 98/01133		AIBE, et al.	01-15-1998
RA	WO	WO 98/01428		DOMINGUEZ, et al.	01-15-1998
RA	WO	WO 98/05536		MARQUIS, et al.	02-12-1998
RA	WO	WO 98/08802		YAMASHITA, et al.	03-05-1998
RA	WO	WO 98/08857		SHIONOGI, et al.	03-05-1998
RA	WO	WO 98/21188		PRESTON, et al.	05-22-1998
RA	WO	WO 98/23588		FLOYD, C.	06-04-1998

Examiner Signature	/Rebecca Anderson/	Date Considered	06/13/2006
-----------------------	--------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-88)
Approved for use through 10/31/98. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Collection of information unless it contains a valid OMB control number.

Under the Patent and Trademark Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for Form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				<p>Complete if Known</p> <table border="1"> <tr> <td>Application Number</td> <td>10/719,080</td> </tr> <tr> <td>Filing Date</td> <td>11-21-2003</td> </tr> <tr> <td>First Named Inventor</td> <td>GRAUPE</td> </tr> <tr> <td>Group Art Unit</td> <td>1626</td> </tr> <tr> <td>Examiner Name</td> <td>Anderson, Rebecca</td> </tr> </table>		Application Number	10/719,080	Filing Date	11-21-2003	First Named Inventor	GRAUPE	Group Art Unit	1626	Examiner Name	Anderson, Rebecca
Application Number	10/719,080														
Filing Date	11-21-2003														
First Named Inventor	GRAUPE														
Group Art Unit	1626														
Examiner Name	Anderson, Rebecca														
Sheet	5	of	13	Attorney Docket Number	USAV2001/0082 - US - CNT										

Examiner Signature	/Rebecca Anderson/	Date Considered	06/13/2006
--------------------	--------------------	-----------------	------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT BEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → Approved for use through 10/31/99. OMB 0651-0091
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/719,080		
Sheet	6	of	13	Attorney Docket Number	USAV2001/0082 - US - CNT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
RA		ADAMS, et al., Potent and Selective Inhibitors of the Proteasome: Dipeptidyl Boronic Acids, <i>Bioorganic & Medicinal Chemistry Letters</i> , 8: 333-338 (1998).	
RA		ASHWORTH, et al., 4-Cyanothiazolidides as very potent, stable inhibitors of dipeptidyl peptidase IV, <i>Bioorganic & Med. Chem. Letters</i> , 8(22):2745-2748 (1998).	
RA		BERGEMAN, et al., Studies on the reactivity of alpha-cyano, alpha-leucyano alkanoates. Versatile synths for the assembly of imidazoles, <i>Helv.Chim. ACTA</i> , 82(8):909-918 (1999).	
RA		BILLSON, et al., The Design and Synthesis of Inhibitors of the Cysteiny1, <i>Bioorg. Med. Chem. Lett.</i> vol. 8, pp. 993-998, 1998	
RA		BROMME, et al., Potent Inactivation of Cathepsins S and L, <i>Biol. Chem. Hoppe-Seyler</i> vol. 375, No. 5, pp. 343-347, 1994.	
RA		CHATTERJEE, et al., D-Amino Acid Containing, High-Affinity Inhibitors of Recombinant Human Calpain I, <i>Journal of Medicinal Chemistry</i> , vol. 41, No. 15, p: 2663-2666 (1998).	
RA		COHEN, et al., Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders, <i>Journal of Neuroimmunology</i> , 88: 29-36 (1999).	
RA		DUFOUR, et al., Engineering nitrile hydratase activity into a cysteine protease by a single mutation, <i>Biochemistry</i> , US, Am. Chem. Soc., Easton, PA, 34(50):16382-16388 (1995).	
RA		EDWARDS, et al., Design, Synthesis, and Kinetic Evaluation of a Unique Class of Elastase Inhibitors, the Peptidyl α -Ketobenzoxazoles, and the X-ray Crystal Structure of the Covalent Complex between Porcine Pancreatic Elastase and Ac-Ala-Pro-Val-2-Benzoxazole, <i>Journal of American Chemical Society</i> , vol. 114, No. 5, p 1854-1869 (1992).	
RA		EVOLI, et al., abstract only, <i>Drugs</i> , 1998, 62(5), 682-70	

Examiner Signature	/Rebecca Anderson/	Date Considered	06/13/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449b/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
(use as many sheets as necessary)			
Sheet	7	of	13
		Attorney Docket Number	USA2001/0082 - US - CNT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
RA		GOUR-SALIN, et al., Inhibition of papain by peptide nitriles: conversion of the nitrile group into other functionalities via the papain-nitrile thiimidate ester adduct, Can. J. of Chem., CA, National Research Council, Ottawa, 69(8):1288-1297 (1991).		
RA		HALLEGUA, et al., Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature, Lupus, 9: 241-251 (2000).		
RA		HANZLIK, et al., Reversible covalent binding of peptide nitriles to papain, Biochim. Biophys. Acta, vol. 1035, No. 1, 1990, pp. 62-70.		
RA		HARRIS, et al., Characteristics of a continuous fluorogenic assay for calpain I. Kinetic evaluation of peptide aldehydes, halomethyl ketones and (achalasida) methyl ketone as inhibitors of the enzyme, Chemical Abstracts, 110:7, Bioorg. Med. Chem. Lett, 5(4) 393-398 (1995).		
RA		HEITMILLER, R.F., abstract only., Semin. Thorac. Cardiovasc. Surg., 1989, 11(1), 41-6		
RA		KATRITZKY, et al., Benzotriazole-assisted synthesis of alpha-(acylamino) nitriles and a conceptually novel method for peptide elongation, Chem. Soc., Perkin Trans. 1(7):1853-1857 (1990).		
RA		KHAMASHTA, et al., Expert. Opin. Investig. Drugs, 2000, 9(7), 1591-93.		
RA		KRANTZ, et al., Peptidyl (Acyl oxy)methyl Ketones and the Quiescent, Biochemistry, vol. 30, pp. 4678-4687, 1991		
RA		LEVY, E.G., Ballerias Clin. Endocrinol. Metab., 1997, 11(3) 585-695		
RA		LI, et al., Aminoacylpyrrolidine-2-nitriles: Potent and stable inhibitors of dipeptidyl-peptidase IV (CD 26), Archives of Biochem. and Biophys., 323(1)146-154 (1995).		

Examiner Signature	/Rebecca Anderson/	Date Considered	06/13/2006
--------------------	--------------------	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Unique citation designation number. ³Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/719,080
(use as many sheets as necessary)		Filing Date	11-21-2003
Sheet	8	of	13
		First Named Inventor	GRAUPE
		Group Art Unit	1626
		Examiner Name	Anderson, Rebecca
		Attorney Docket Number	USA2001/0082 - US - CNT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
RA		LIPSHUTZ, et al., Chiral induction in orthoglycine racemic amino acids via 5-acyl and 5-acyloxyaminocoxazoles, Isr. J. Chem. 27(1):49-55 (1988), abstract.	T2
RA		LIPSHUTZ, et al., Heterocycles as masked diamide/dipeptide equivalents. Formation and reactions of substituted 5-(acylamino)oxazoles as intermediates en route to the cyclopeptide alkaloids, J. Am. Chem. Soc., 105(26):7703-7713 (1983).	
RA		LIPSHUTZ, et al., Oxazolophanes as masked cyclopeptide alkaloid equivalents: cyclic peptide chemistry without peptide couplings, J. Am. Chem. Soc., 112(19):7032-7041 (1990).	
RA		MARQUIS, et al., Potent dipeptidylketone inhibitors of the cysteine protease cathepsin, Chemical Abstracts, 7:4 581-588 (1999).	
RA		MCMATH, et al., Direct dialkylation of peptide nitriles. Application of the synthesis of 1-aminocyclopropane-1-carboxylic acid (Acc)-containing dipeptides, Bull. Soc. Chim. Fr. 194(1):105-110 (1997).	
RA		MORIYA, et al., Synthesis and Hypolipidemic Activities of 5-Thienyl-4-oxazoleacetic Acid Derivatives, J. Med. Chem., 29: 333-341 (1986).	
RA		MOSER, et al., 130 Poly (dipeptidinium)-Salze: definition und methoden zur präparativen herstellung, poly (dipeptidinium) salts: definition and methods of preparation, Helvetica Chimica ACTA, CH, Verlag, Basel 69:1224-1262 (1986).	
RA		NIPPON, K., Patent Abstracts of Japan, Publication No. 63301888, 019(137)(1988), abstract.	
RA		NORTH, et al., Synthetic studies towards cyclic peptides. Concise synthesis of thiazoline and thiazole containing amino acids, Tetrahedron, 46(24):8627-8290 (1990).	
RA		OGILVIE, et al., Peptidomimetic inhibitors of the human cytomegalovirus protease, Journal of Medicinal Chemistry vol. 40 No. 25 (1997).	

Examiner Signature	/Rebecca Anderson/	Date Considered	06/13/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/88B (10-05)

Approved for use through 10/31/08. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/719,080		
Sheet	9	of	13	Attorney Docket Number	USAV2001/0082 - US - CNT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RA		PICKEN, et al., Inhibition of bovine cathepsin B by amino acid-derived nitriles, Biochemical Society Transactions, vol. 18, No. 2, p.318 (1990).	
RA		PLIURA, et al., Comparative behavior of calpain and cathepsin B , Biochem. J. vol. 288, pp. 759-762, 1992	
RA		POLMAN, et al., Drug treatment of multiple sclerosis , BMJ, 321: 19-26 (2000).	
RA		RIESE, et al., Essential Role for Cathepsin S In MHC Class II-Associated Invariant Chain Processing and Peptide Loading, Immunity, 4: 357-366 (Apr. 1996).	
RA		SMITH, et al., New Inhibitors of Cysteine Proteinases, J. Am. Chem. Soc. vol. 110, No. 13, pp. 4429-4431, 1988	
RA		SUAVE, et al., Carboxylmodified amino acids and peptides, I An efficient method for the synthesis of monofunctionalized enamines and monofunctionalized methyl ketone derivatives from thioamides via episcufides and thioiminium salts, Tetrahedron Lett, 29:19 2295-2298 (1988).	
RA		SUZUE, S., Hepatic agents. I. Synthesis of aminocyl (and hydroxyacyl) aminoacetonitriles, Chem. and Pharm. Bull. (Tokyo) (1969), 16(8), 1417-32.	
RA		SUZUE, et al., Studies on Hepato Agents , Chem. Pharm. Bull. vol. 18, No. 8, pp. 1417-1432, Aug. 1988.	
RA		SUZUKI, et al., Synthesis of 2-Aryl-4-(3-thienyl)imidazole Derivatives with Antinflammatory Properties .sup.1), Chem. Pharm. Bull, 34(8): 3111-3120 (1986).	
RA		TAO, et al., Inhibition of Calpain By Peptidyl Heterocycles, Bioorganic & Medicinal Chemistry Letters, 6:24 3009-3112 (1996).	

Examiner Signature	/Rebecca Anderson/	Date Considered	06/13/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → Approved for use through 10/31/95. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/719,080
(use as many sheets as necessary)				Filing Date	11-21-2003
Sheet	10	of	13	First Named Inventor	GRAUPE
				Group Art Unit	1626
				Examiner Name	Anderson, Rebecca
				Attorney Docket Number	USAV2001/0082 - US - CNT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RA		THOMPSON, et al., Carboxyl-modified amino acids and peptides as protease inhibitors, J. Med. Chem., 29(1):104-111 (1986).	
RA		TSUTSUMI, et al., Synthesis and Structure-Activity Relationships of Peptidyl α -Keto Heterocycles as Novel Inhibitors of Prolyl Endopeptidase, Journal of Medicinal Chemistry, vol. 37, No. 21, p 3492-3502 (1994).	
RA		VARGHA, E., Peptide derivatives. VI. N-protected di- and tripeptide nitriles, Stud. Univ. Babes-Bolyai, Ser. Chem., 13(2):31-6 (English abstract of article in Romanian) (1968).	
RA		VARGHESE, The structure and resonance Raman spectra-structure correlations for methyloxycarbonyl-L-phenylalanyl-L-alanine ethyl dithioester, Can. J. Chem., 64(8):1668-1673 (1986).	
RA		YAMADA, et al., Studies of unusual amino acids and their peptides. IX. The synthetic study of bottromycin B1 and B2, Bul. Chem. Soc., Jpn. 51(3):878-83 (1978), abstract.	
RA		, Derwent Abstract of Japanese Patent Application 06-192199 , (Jul. 12, 1994).	

Examiner Signature	/Rebecca Anderson/	Date Considered	06/13/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

Approved for use through 10/31/89. OMB 0631-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Use of this form is mandatory; it contains no confidential information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/718,080
				Filing Date	11-21-2003
				First Named Inventor	GRAUPE
				Group Art Unit	1626
				Examiner Name	Anderson, Rebecca
Sheet	11	of	13	Attorney Docket Number	USAV2001/0082 - US - CNT

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
RA	JP	JP 2001-011037			SATO, et al.	01-16-2001		
RA	JP	JP 2001-055368			SATO, et al.	02-27-2001		
RA	WO	WO00/59881			SINGH, et al.	10-12-2000		
RA	WO	WO01/09169			SINGH, et al.	02-08-2001		
RA	WO	WO02/057248			QUIBELL, et al.	07-25-2002		
RA	WO	WO02/057249			QUIBELL, M	07-25-2002		
RA	WO	WO02/057270			QUIBELL, M	07-25-2002		
RA	WO	WO02/096892			OHMOTO, et al.	05-30-2002		
RA	WO	WO02/100848			HICKEY, et al.	12-19-2002		
RA	WO	WO02/20485			BEKKALI, et al.	03-14-2002		

Examiner Signature	/Rebecca Anderson/	Date Considered	06/13/2006
-----------------------	--------------------	--------------------	------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached *Kinds of U.S. Patent Documents*. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → Approved for use through 10/31/99. OMB 0651-0001
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 14498/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/719,080
(use as many sheets as necessary)				Filing Date	11-21-2003
Sheet	12	of	13	First Named Inventor	GRAUPE
				Group Art Unit	1626
				Examiner Name	Anderson, Rebecca
				Attorney Docket Number	USA2001/0082 - US - CNT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), etc. of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
RA		CHAPMAN, et al., Emerging Roles for Cysteine Proteases in Human Biology, <i>Ann. Rev. Physiol.</i> ; 1997; 59; pp.63-88.		T ²
RA		DRANOFF, et al., Cathepsin S Required for Normal MHC Class II Peptide Loading and Germinal Center Development, <i>Immunity</i> ; 1999; 10; pp.197-206.		
RA		FENWICK, et al., Diastereoselective Synthesis, Activity and Chiral Stability of Cyclic Alkoxyketone Inhibitors of Cathepsin K, <i>Bioorg. Med. Chem. Lett.</i> ; 2001; 11(2); pp.199-202.		
RA		FENWICK, et al., Solid-phase Synthesis of Cyclic Alkoxyketones, Inhibitors of the Cysteine Protease Cathepsin K, <i>Bioorg. Med. Chem. Lett.</i> ; 2001; 11(2); pp.185-190.		
RA		GREENSPAN, et al., Identification of Dipeptidyl Nitriles as Potent and Selective Inhibitors of cathepsin B Through Structure-based Drug Design, <i>J. Med. Chem.</i> ; 2001; 44; pp.4524-4534.		
RA		LOWE, et al., Kinetic Specificity in Papain-catalyzed Hydrolyses, <i>Biochem. J.</i> ; 1971; 124(1); pp.107-115.		
RA		MACIEWICZ, et al., A comparison of Four Cathepsins (B,L,N and S) with Collagenolytic Activity From Rabbit Spleen, <i>Biochem J.</i> ; 1998; 266; pp.433-440.		
RA		MARQUIS, et al., Azeanone-based Inhibitors of Human and Rat Cathepsin K, <i>J. Med. Chem.</i> ; 2000; 44(9); pp.1380-1395.		
RA		NAKAGAWA, et al., Impaired Invariant Chain Degradation and Antigen Presentation and Diminished Collagen-induced Arthritis in Cathepsin S-null Mice, <i>Immunity</i> ; 1999; 10; pp.207-217.		
RA		OTTO, et al., Cysteine Proteases and their Inhibitors, <i>Chem. Rev.</i> ; 1997; 97; pp.133-171.		

Examiner Signature	/Rebecca Anderson/	Date Considered	06/13/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/085 (10-86)

Approved for use through 10/31/89. OMB 0651-0031

<p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				<p>Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE</p> <p>Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.</p>	
				<p>Complete if Known</p>	
<p>Application Number</p>		<p>10/719,080</p>			
<p>Filing Date</p>		<p>11-21-2003</p>			
<p>First Named Inventor</p>		<p>GRAUPE</p>			
<p>Group Art Unit</p>		<p>1626</p>			
<p>Examiner Name</p>		<p>Anderson, Rebecca</p>			
<p>Attorney Docket Number</p>		<p>USAV2001/0082 - US - CNT</p>			
Sheet	13	of	13		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Signature	/Rebecca Anderson/	Date Considered	06/13/2006
-------------------------------	--------------------	----------------------------	------------

***EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.